Hypoglycemia associated with non-islet cell tumors

Area of Science:

• Endocrinology
• Oncology
• Metabolic Disorders

Background:

• Tumor hypoglycemia is a rare but serious condition.
• It is often associated with insulinoma or non-islet cell tumors, particularly those of mesenchymal origin.
• The underlying cause involves abnormal processing of insulin-like growth factor-2 (IGF-2).

Purpose of the Study:

• To elucidate the pathogenesis of tumor hypoglycemia.
• To identify key laboratory markers associated with this condition.
• To emphasize the importance of considering tumor hypoglycemia in unexplained hypoglycemia cases.

Main Methods:

• Analysis of the biochemical pathways involved in IGF-2 precursor processing.
• Evaluation of laboratory findings including fasting glucose, C-peptide, IGF-1, and IGF-2 levels.
• Review of clinical presentations and diagnostic considerations.

Main Results:

• Pathognomonic "big" IGF-2, an incompletely processed precursor, is identified as the cause of hypoglycemia.
• Typical laboratory findings include low fasting glucose, low C-peptide, low IGF-1, and an elevated IGF-2:IGF-1 ratio.
• Paraneoplastic hypoglycemia can be a presenting sign of malignancy.

Conclusions:

• Understanding the role of "big" IGF-2 is crucial for diagnosing tumor hypoglycemia.
• Prompt diagnosis and treatment of tumor hypoglycemia can significantly improve quality of life.
• This condition warrants consideration in patients with unexplained hypoglycemia, even without a prior cancer diagnosis.